Background: We aimed to investigate the efficacy and safety of landiolol in Japanese patients with recurrent hemodynamically unstable ventricular tachycardia or recurrent ventricular fibrillation (recurrent VT/VF).
Methods and results: This was an open-label, uncontrolled, multicenter study. Patients with hemodynamically unstable VT or VF 24 h prior to providing informed consent, and who were refractory to class III antiarrhythmic drugs, were enrolled. Landiolol was started at a dose of 1 μg/kg/min, after VT/VF was suppressed with electrical defibrillation. Landiolol was titrated up to 10 μg/kg/min in 1 h and adjusted between 1 and 40 μg/kg/min for the efficacy assessment (1-49 h). The primary efficacy endpoint was the proportion of patients free from recurrent VT/VF. Secondary efficacy endpoints included the number of recurrent VT/VF events and the survival rate 30 days after the start of landiolol treatment. Adverse events (AEs) were assessed for safety; 27 and 29 patients were analyzed for efficacy and safety, respectively. The proportion of patients free from recurrent VT/VF was 77.8% (95% CI 57.1-89.3). The mean (±standard deviation) number of recurrent VT/VF events was 9.3±7.9. The survival rate was 96.3%. The overall incidence of AEs and of serious AEs was 72.4% and 6.9%, respectively.
Conclusions: Landiolol may be useful for Japanese patients with recurrent VT/VF who do not respond to class III antiarrhythmic drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1253/circj.CJ-18-1361 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epicardial Substrate Ablation in Symptomatic Brugada Syndrome Patients: An Updated Systematic Review and Single-arm Meta-analysis.
Heart Rhythm
January 2025
Dante Pazzanese Institute of Cardiology, Department of Electrophysiology, São Paulo, Brazil.
Background: Brugada syndrome (BrS) is a genetic heart disease that predisposes individuals to ventricular arrhythmias and sudden cardiac death. Although implantable cardioverter-defibrillators (ICDs) and quinidine are primary treatments, recurrent BrS-triggered ventricular arrhythmias can persist. In this setting, epicardial substrate ablation has emerged as a promising alternative for symptomatic patients.
View Article and Find Full Text PDFExtracorporeal membrane oxygenation for patients with electrical storm or refractory ventricular arrhythmias: Management and outcomes.
Can J Cardiol
December 2024
Department of Medicine, University of Toronto, Toronto, Canada; Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Canada. Electronic address:
Patients on veno-arterial extracorporeal membrane oxygenation (VA-ECMO) are at high risk for ventricular arrhythmias due to derangements in myocardial perfusion, hemodynamics, and heightened catecholamine states. Existing data on the management and outcomes of patients with electrical storm or refractory ventricular tachycardia/fibrillation (VT/VF) treated with VA-ECMO are primarily derived from retrospective observational studies. Typical survival rates are in the range of 40-50%, with 15-20% of patients undergoing VT ablation and 30-40% of patients requiring advanced heart failure therapies (cardiac transplant or durable left ventricular assist device).
View Article and Find Full Text PDFExploring Cardiac Sympathetic Denervation as a Treatment Approach for Recurrent Ventricular Arrhythmias: A Concise Review.
J Clin Exp Cardiolog
March 2024
Division of Thoracic Surgery, Johns Hopkins University School of Medicine, Baltimore, USA.
Article Synopsis
- * Bilateral CSD (BCSD) shows an approximate 60% reduction in implantable cardioverter defibrillator shocks and over 50% one-year survival without shock or transplant, while the 2017 guidelines endorse the left CSD for specific RVT types.
- * Despite the promising results, many studies have small sample sizes leading to potential underreporting of complications; more research is needed to fully understand the long
Dofetilide for the treatment of premature ventricular complexes and ventricular tachycardia in patients with structural heart disease.
J Cardiovasc Electrophysiol
December 2024
Division of Cardiovascular Medicine, Cardiac Arrhythmia Service, University of Michigan, Ann Arbor, Michigan, USA.
Article Synopsis
- - Dofetilide, a class III antiarrhythmic, is used to treat atrial fibrillation and flutter, and has been applied off-label for ventricular arrhythmias like PVCs and VTs.
- - In a study involving 81 patients, dofetilide initiation showed a significant decrease in PVC burden, but was discontinued in some cases due to QT prolongation and lack of efficacy.
- - Overall, 72% of patients had to stop dofetilide due to inefficacy or intolerance, and there was no significant difference in event-free survival between those treated with dofetilide and those who weren't.
Clinical Course and Treatment of Patients With Apical Aneurysms Due to Hypertrophic Cardiomyopathy.
JACC Adv
October 2024
Cardiomyopathy Program, Mount Sinai West and Mount Sinai Morningside, New York City, New York, USA.
Article Synopsis
- In patients with hypertrophic cardiomyopathy (HCM), the study aimed to evaluate the relationship between apical aneurysm size and common risk factors with the occurrence of deadly arrhythmias and unexplained strokes.
- Among 108 patients studied, 19.4% experienced events like sudden cardiac death or serious arrhythmias, with a significant risk linked to larger aneurysm sizes and the presence of major HCM risk factors.
- Atrial fibrillation was common, and while stroke incidence was low without known causes, overall findings suggest that smaller aneurysms (less than 2 cm) pose a lower risk for severe events over five years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!